Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...
Siemens Healthineers has tapped the Alzheimer’s disease blood test developer ALZpath for an in vitro diagnostic to ...
Vivek Ramaswamy has found time out of his campaign for governor of Ohio to launch a new biotech. | Vivek Ramaswamy has found ...
Aldeyra submitted the single successful trial to the FDA over the summer and the agency accepted the resubmitted NDA for ...
Through a potential $1.37 billion deal, New York-headquartered Yarrow gains ex-China rights to a potential first-in-class ...
A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and ...
After Generation Bio telegraphed plans to lay off 90% of its staff this summer, Xoma Royalty has come knocking to bring yet ...
The FDA said it plans to accept new forms of real-world evidence in product applications, starting with a subset of medical ...
The FDA has cleared an augmented reality platform for real-time use during brain surgery—which its developer, Medivis, ...
MapLight Therapeutics is the latest biotech to want a turn with Alphabet’s AI spinout SandboxAQ. | MapLight Therapeutics is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback